Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
PTC Therapeutics
With
The John Walton Muscular Dystrophy Research Centre (TREAT-NMD)
Cooperative International Neuromuscular Research Group
This is a multicenter, observational study of participants receiving Translarna based on inclusion of their data in a registry. This study is intended to enroll 360 participants across \~50 care centers in Europe and other regions over a period of \~ 2 years. The study population will include participants who are receiving usual care treatment with commercial supply of Translarna (or receiving care within a named participant early access program) and who provide consent. Participants will be followed for at least 5 years from their date of enrollment. Safety and efficacy data will be collected in conjunction with routine visits conducted as per usual care. Although there are no protocol-mandated procedures, it is expected that physicians and other caregivers will follow published treatment guidelines and standards of care.
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Receiving or will be receiving usual care treatment with commercial supply of Translarna (or receiving care within a named participant early access program)
Willing to provide written informed consent to allow the study data collection procedures (either by the participant or through authorisation by a legal guardian)
You may not be if
Participants who are receiving ataluren or placebo in a blinded, randomized clinical trial, or ataluren in any other ataluren clinical trial or cohort early access program that prevents participation in this study